NCT04597372View on ClinicalTrials.gov

Impact of Tamsulosin on Post-Operative Urinary Retention Following Pelvic Reconstructive Surgery

PHASE2RecruitingINTERVENTIONAL
Enrollment

154

Participants

Timeline

Start Date

November 3, 2021

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions
Urinary Retention Postoperative
Interventions
DRUG

Tamsulosin

Study drug will contain 0.4 mg of Tamsulosin. Subjects will be provided with 10 capsules to be taken daily.

DRUG

Placebo

Placebo will be prepared by the IDS pharmacist (or contracted pharmacy) and encapsulated in identical appearing wraps. Subjects will be provided with 10 capsules to be taken daily.

Trial Locations (1)

15224

RECRUITING

West Penn Hospital, Pittsburgh

All Listed Sponsors
collaborator

Johns Hopkins University

OTHER

lead

Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)

OTHER